Mount Sinai Names Dudley Leader of New Precision Health Enterprise
Mount Sinai Health System has created a Precision Health Enterprise to draw on the expertise of both its health system and the Icahn School of Medicine. To oversee this enterprise, the health system also created a new role: executive vice president for precision health.
Taking on the new role is Joel Dudley, Ph.D., director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai (ISMMS). In this new role, Dudley will be responsible for linking research conducted in the ISMMS with implementation strategies developed in collaboration with leadership and staff throughout the Health System.
Mount Sinai said the Precision Health Enterprise would focus on three key strategies:
- Intelligent Health Care – Artificial intelligence and predictive analysis will be applied to improve disease detection, treatment, and prevention. The school’s multidisciplinary Precision Medicine initiative will be central to data collection, generation, analysis, and application.
- Consumer Health and Wellness – Moving beyond the hospital experience to manage the total health of our patients, the Enterprise will develop approaches to improve patient health and avoid hospitalization whenever possible.
- External Partnerships – Recognizing the rapidly changing landscape of health care delivery and insurance, the Enterprise will forge new relationships with industry, particularly technology companies, to optimize quality of care and cost-effectiveness.
Dudley will work closely with Niyum Gandhi, the Health System’s Executive Vice President and Chief Population Health Officer, and Prabhjot Singh, M.D., Ph.D., Chair, Department of Health Systems Design and Global Health, and Director, The Arnhold Institute of Global Health at ISMMS.
“Mount Sinai is harnessing data from our large and diverse patient population to treat and heal patients, as well as develop a next-generation learning health system,” Dudley said in a prepared statement. “Our goal with the Precision Health Enterprise is to continue to personalize therapies for our patients, including those with conditions such as cancer, chronic diseases such as diabetes and Alzheimer’s disease, or rare genetic conditions. We believe that new product development, prototyping, artificial intelligence, predictive analysis, prevention, and partnerships will help us deliver better care in a rapidly changing health care ecosystem.”
Dudley will continue in his role as director of the Institute for Next Generation Healthcare at ISMMS. He is developing an integrated translational biomedical research model at the nexus of advances in omics, clinical medicine, digital health, and artificial intelligence. Under his leadership, the Institute has established a Next Generation Health Clinic in Manhattan to translate discoveries from computational data-driven approaches into personalized health care delivery to patients. Additionally, a Health Data and Design Innovation Center created in Silicon Valley expands the Institute’s ability to pursue innovations and develop programs that partner with emerging health technology startups. These initiatives dovetail with the goals of the Precision Health Enterprise.